MX2023006938A - Compuestos inhibidores multicíclicos de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y usos de estos. - Google Patents
Compuestos inhibidores multicíclicos de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y usos de estos.Info
- Publication number
- MX2023006938A MX2023006938A MX2023006938A MX2023006938A MX2023006938A MX 2023006938 A MX2023006938 A MX 2023006938A MX 2023006938 A MX2023006938 A MX 2023006938A MX 2023006938 A MX2023006938 A MX 2023006938A MX 2023006938 A MX2023006938 A MX 2023006938A
- Authority
- MX
- Mexico
- Prior art keywords
- flt3
- irak
- compounds
- compositions
- inhibiting compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129895P | 2020-12-23 | 2020-12-23 | |
| PCT/US2021/065037 WO2022140647A1 (en) | 2020-12-23 | 2021-12-23 | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006938A true MX2023006938A (es) | 2023-10-13 |
Family
ID=82158501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006938A MX2023006938A (es) | 2020-12-23 | 2021-12-23 | Compuestos inhibidores multicíclicos de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y usos de estos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12612410B2 (https=) |
| EP (1) | EP4267142A4 (https=) |
| JP (1) | JP2024501658A (https=) |
| CN (1) | CN117015380A (https=) |
| AU (1) | AU2021410783A1 (https=) |
| CA (1) | CA3201841A1 (https=) |
| IL (1) | IL303887A (https=) |
| MX (1) | MX2023006938A (https=) |
| WO (1) | WO2022140647A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023250431A2 (en) * | 2022-06-22 | 2023-12-28 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009507032A (ja) * | 2005-09-02 | 2009-02-19 | アボット・ラボラトリーズ | 新規なイミダゾ系複素環 |
| BRPI1014572B8 (pt) * | 2009-04-16 | 2022-07-19 | Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii | Imidazopirazinas para uso como inibidores de cinase |
| WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
| US8673905B2 (en) * | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
| WO2014210255A1 (en) | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| US10138248B2 (en) * | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
| US11542261B2 (en) * | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
| US11254667B2 (en) | 2016-08-17 | 2022-02-22 | Children's Hospital Medical Center | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors |
| DK3500571T3 (da) * | 2016-08-17 | 2021-03-08 | Childrens Hospital Med Ct | Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf |
| TW201822764A (zh) * | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| TW201841916A (zh) | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | 芳香烴受體拮抗劑及其用途 |
| WO2019002606A1 (en) * | 2017-06-30 | 2019-01-03 | Selvita S.A. | ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS |
-
2021
- 2021-12-23 CA CA3201841A patent/CA3201841A1/en active Pending
- 2021-12-23 AU AU2021410783A patent/AU2021410783A1/en active Pending
- 2021-12-23 IL IL303887A patent/IL303887A/en unknown
- 2021-12-23 WO PCT/US2021/065037 patent/WO2022140647A1/en not_active Ceased
- 2021-12-23 US US18/258,586 patent/US12612410B2/en active Active
- 2021-12-23 CN CN202180093913.0A patent/CN117015380A/zh active Pending
- 2021-12-23 JP JP2023537923A patent/JP2024501658A/ja active Pending
- 2021-12-23 EP EP21912215.7A patent/EP4267142A4/en active Pending
- 2021-12-23 MX MX2023006938A patent/MX2023006938A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117015380A (zh) | 2023-11-07 |
| AU2021410783A9 (en) | 2024-10-17 |
| IL303887A (en) | 2023-08-01 |
| US20240294530A1 (en) | 2024-09-05 |
| US12612410B2 (en) | 2026-04-28 |
| AU2021410783A1 (en) | 2023-08-10 |
| EP4267142A1 (en) | 2023-11-01 |
| CA3201841A1 (en) | 2022-06-30 |
| WO2022140647A1 (en) | 2022-06-30 |
| JP2024501658A (ja) | 2024-01-15 |
| EP4267142A4 (en) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023006937A (es) | Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos. | |
| MX2023001997A (es) | Compuestos biciclicos, composiciones y usos de los mismos. | |
| Luongo et al. | Possible therapeutic effects of ozone mixture on hypoxia in tumor development | |
| MX2024001193A (es) | Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a sarcoma felino de mcdonough (flt3) y usos de estos. | |
| ES2617689T3 (es) | Combinación terapéutica que comprende un inhibidor de PLK1 y un agente antineoplásico | |
| TNSN07341A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| TW200740762A (en) | Pyrazole compounds that modulate HSP90 activity | |
| IL184872A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
| IL185063A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
| WO2021222542A8 (en) | 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders | |
| MX2009007777A (es) | Terapia de combinacion que comprende romidepsina y bortezomib. | |
| MX2023006938A (es) | Compuestos inhibidores multicíclicos de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y usos de estos. | |
| BR112023026452A2 (pt) | Conjugados de fármacos peptídicos | |
| WO2023245123A3 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| WO2023150601A3 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| IL197513A0 (en) | Pyrazolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| UY30175A1 (es) | Combinacion farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas | |
| PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| WO2020232191A8 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer | |
| WO2023250431A3 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| WO2024163764A3 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| MX2024005722A (es) | Terapia de combinacion para el tratamiento del cancer de pulmon. | |
| CR20240016A (es) | Compuestos terapéuticos y procedimientos | |
| BR112023017116A2 (pt) | Composição farmacêutica combinada contendo inibidor de cdk4/6 e uso da mesma |